Recently, the European Association of Neuro-Oncology (EANO) stratified IDH-mutant gliomas into three WHO grades: oligodendroglioma, WHO grade 2 or 3; astrocytoma, WHO grade 2 or 3; astrocytoma, WHO grade 4 [5]. Here, IDH2 is linked to central nervous system cancer.